“We are pleased to welcome Hansa Medical to Nasdaq Stockholm's main market. Hansa Medical joins our growing healthcare sector and we look forward to supporting them with the increased investor visibility that comes with a main market listing”, said Adam Kostyál, senior vice president and head of European listings at Nasdaq.

“In 2015, we have made significant progress in our prioritized clinical development programs. Our vision is to build a sustainable biopharmaceutical company with pharmaceuticals that significantly improve health outcomes in patients. We are getting the cornerstones in place for future growth. The upgrade to Nasdaq Stockholm’s main market has the potential to make Hansa Medical even more attractive to existing and new investors”, said Göran Arvidson, President and CEO of Hansa Medical AB.

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on November 2, 2015 at 10.00 CET.